Authors
Dr. Sreejith N Kumar, Convener, Research Cell, IMA Kerala State, K-5, Kochar Road, Sasthamangalam Thiruvananthapuram-695010.
Abstract
The gastrointestinal hormones glucose- dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), termed incretins, are essential regulators of normal glucose homeostasis. The drug substance, Liraglutide, is a long acting analogue of the naturally occurring human GLP-1 (7-37) with 97% homology and a lipophilic substituent for prolongation of half life.
Liraglutide is available in a pre-filled, multi-dose pen-injector containing 6.0 mg/ml of the drug substance in solution presented for subcutaneous injection.
Liraglutide provided significantly better glycemic control than Rosglitazone or insulin glargine in combination trials. Liraglutide improved pancreatic beta-cell function, consistently led to weight loss, and was associated with a low risk of hypoglycaemia. Liraglutide was generally well tolerated, with the most common adverse events being gastrointestinal events, such as nausea, which decreased over time.
Keywords: GLP 1 Analogue, Liraglutide, Incretin, Hypoglycemia, Weight loss.